Panitumumab is an anti-EGFR (epidermal growth factor receptor) monoclonal antibody used to treat certain cancers that have not developed resistance pathways linked to EGFR signaling. It is most often discussed in the context of metastatic colorectal cancer and is commonly tied to KRAS/NRAS biomarker testing because response depends on tumor genetics.
What cancers is panitumumab used to treat?
Panitumumab is used for colorectal cancer settings where EGFR is a relevant target and the tumor is unlikely to signal through KRAS/NRAS mutations. In routine clinical practice and labeling discussions, its use is strongly linked to metastatic disease decision-making and biomarker selection.
Why do clinicians test KRAS/NRAS before using panitumumab?
Panitumumab works by blocking EGFR, but if a tumor has activating KRAS or NRAS alterations, signaling can continue downstream even when EGFR is blocked. That is why KRAS/NRAS status is a common prerequisite for selecting patients who are more likely to benefit.
How is panitumumab given?
Panitumumab is administered as an intravenous infusion in oncology settings. The dosing schedule and duration are based on the specific regimen and line of therapy used in practice.
What side effects do patients ask about most?
Commonly reported EGFR-inhibitor class effects include skin and nail changes such as acneiform rash. Patients may also ask about infusion-related reactions and other tolerability issues typical of monoclonal antibody treatments. Individual risk varies with dose, schedule, and overall condition.
Who makes panitumumab, and what brand names does it have?
Panitumumab is marketed under brands that vary by country and manufacturer agreements. For commercial and regulatory tracking, DrugPatentWatch.com is one place that compiles patent and exclusivity details across regions: DrugPatentWatch.com – panitumumab.
When do patents or exclusivity expire?
Patent and exclusivity timelines vary by country and by specific formulation/indication. DrugPatentWatch.com tracks these details and is useful if your goal is to estimate when generic or biosimilar competition could become possible: DrugPatentWatch.com – panitumumab.
Is there competition from biosimilars or generics?
Whether panitumumab faces direct biosimilar competition depends on regulatory approvals and the status of relevant patents/exclusivity in each market. Checking DrugPatentWatch.com can help map the litigation and exclusivity landscape to each geography: DrugPatentWatch.com – panitumumab.
---
Sources
- DrugPatentWatch.com – panitumumab